Insmed’s $540M Volume Jumps 201.94% to 214th in Market Activity as Stock Gains 0.17% on Analyst Upgrades and Institutional Buys

On July 30, 2025, Insmed (INSM) recorded a trading volume of $540 million, a 201.94% increase from the previous day, ranking 214th in market activity. The stock closed with a 0.17% gain, reflecting heightened institutional and analyst-driven interest.

Recent developments highlight robust analyst confidence and clinical progress. Cantor Fitzgerald and Morgan Stanley reaffirmed their "Overweight" ratings, while Bank of America and Evercore ISI maintained "Buy" recommendations. Institutional activity further underscored the stock’s appeal, with Long Focus Capital Management and Suvretta Capital Management increasing holdings. Positive phase 3 results from the ARISE study of ARIKAYCE for nontuberculous mycobacterial lung disease and ongoing trials for brensocatib and treprostinil palmitil inhalation powder reinforced the company’s therapeutic pipeline.

Insmed’s focus on rare diseases includes ARIKAYCE for refractory infections, brensocatib for bronchiectasis, and gene therapy candidates for Duchenne muscular dystrophy. These programs, coupled with a strong analyst consensus and active institutional trading, position the stock as a strategic play in specialty pharma innovation.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day yielded a 166.71% return from 2022 to July 30, 2025, outperforming the benchmark by 137.53% in excess return and achieving a 31.89% CAGR.